Low-dose growth hormone administration mobilizes endothelial progenitor cells in healthy adults

Jessica K. Devin*, Douglas E. Vaughan, Lewis S. Blevins, Qingxia Chen, Joseph Covington, Denise K. Verity, Pampee P. Young

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Objective: Endothelial progenitor cells (EPCs) mobilize from the bone marrow secondary to a stimulus and home to sites of injury, where they differentiate into endothelial cells and contribute to the repair of damaged vasculature. We hypothesized that growth hormone (GH) administration would increase the number of circulating EPCs in adults and thereby represent a mechanism to enhance vascular health. Design: A prospective trial of low-dose GH (0.03 mg/kg/week for 4 weeks followed by 0.06 mg/kg/week for a maximum of four additional weeks) in 10 healthy adults (6 males and 4 females; mean age 37 years, range 26-65). Primary outcomes measured included the number of circulating EPCs as assessed by colony-forming unit (CFU) assay and flow cytometry. Secondary outcomes included plasma measurements of known mediators of EPC mobilization and indices of nitric oxide (NO). Outcomes were measured at baseline and at study completion. Results: GH administration increased serum IGF-1 (143 ng/mL [IQR 121-164] to 222 [IQR 194-244]; P = 0.005). The increase in early-outgrowth EPCs (13 CFU per high-power field [IQR 6-24] to 19 [IQR 13-40]; P = 0.005) correlated with the peak IGF-1 after adjustment for the baseline number of early-outgrowth EPCs (r = 0.719 [95% CI 0.06, 0.93]; P = 0.027). The number of late-outgrowth EPCs as well as CD34+, VEGFR2(KDR)+, and AC133+ cells did not significantly change. Other mediators of EPC mobilization were stable while plasma nitrite trended upwards (1.3 μmol/L [IQR 0-2.5] to 3.7 [IQR 2.2-8.9]; P = 0.052). Conclusions: GH administration selectively augments the early-outgrowth EPC population in healthy individuals. These findings both support GH replacement in the setting of GH deficiency to maintain vascular integrity and have implications for the use of GH in future regenerative cell-based therapies. Furthermore, the decrease in EPCs observed with aging may in part be explained by the declining somatotropic axis, and thereby contribute to cardiovascular senescence.

Original languageEnglish (US)
Pages (from-to)253-263
Number of pages11
JournalGrowth Hormone and IGF Research
Volume18
Issue number3
DOIs
StatePublished - Jun 2008

Keywords

  • Aging
  • Angiogenesis
  • Endothelial function
  • Endothelial progenitor cells
  • Growth hormone
  • Insulin-like growth factor 1

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Low-dose growth hormone administration mobilizes endothelial progenitor cells in healthy adults'. Together they form a unique fingerprint.

Cite this